Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

After acquiring 23andMe, Regeneron Pharmaceuticals has said it will protect user data as it uses DNA data for drug ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

Regeneron acquires bankrupt 23andMe for $256M. What this DNA data sale means for privacy, pharma, and your genetic ...

Genetic testing company 23andMe is being acquired, shortly after it declared bankruptcy months ago.

To acquire Personal Genome Service, Total Health and Research Services business lines, and its Biobank and associated assets.

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...

Regeneron Pharmaceuticals enters into asset purchase agreement to acquire 23andMe for $256 million: Tarrytown, New York Wednesday, May 21, 2025, 13:00 Hrs [IST] Regeneron Pharmace ...